|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.78 USD | -0.93% |
|
-1.77% | -39.03% |
| 12-06 | Glaxosmithkline in collaboration with Muna Therapeutics on Alzheimer's disease | FW |
| 12-05 | Morgan Stanley Adjusts Price Target on Biogen to $192 From $204, Maintains Equalweight Rating | MT |
| Capitalization | 22.99B 21.76B 20.17B 18.04B 32.51B 1,947B 35.98B 251B 92.78B 800B 86.37B 84.45B 3,447B | P/E ratio 2024 * |
12.6x | P/E ratio 2025 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise value | 26.53B 25.1B 23.27B 20.81B 37.51B 2,247B 41.52B 290B 107B 923B 99.66B 97.44B 3,977B | EV / Sales 2024 * |
2.75x | EV / Sales 2025 * | 2.47x |
| Free-Float |
85.83% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -0.93% | ||
| 1 week | -1.77% | ||
| Current month | -1.77% | ||
| 1 month | -9.53% | ||
| 3 months | -21.43% | ||
| 6 months | -31.99% | ||
| Current year | -39.03% |
1 week
157.35
165.29
1 month
153.62175.86
Current year
153.62268.30
1 year
153.62268.30
3 years
153.62319.76
5 years
153.62468.55
10 years
153.62480.18
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 13/11/2022 | |
| Director of Finance/CFO | 60 | 14/08/2020 | |
Nicole Murphy
COO | Chief Operating Officer | - | 31/12/2021 |
| Manager | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 64 | 25/06/2023 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 22/03/2010 |
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/12/2009 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | -.--% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.93% | -1.77% | -32.54% | -29.60% | 22.99B | ||
| -0.31% | -0.50% | +4.99% | -5.22% | 86.88B | ||
| -0.21% | -1.33% | +36.45% | +6.77% | 48.14B | ||
| +0.03% | -0.03% | +145.82% | +90.44% | 37.15B | ||
| +1.33% | +1.78% | +36.99% | +16.78% | 14.63B | ||
| -0.51% | +4.06% | +60.30% | -35.13% | 13.21B | ||
| +0.88% | +1.08% | -29.12% | -20.77% | 12.72B | ||
| -1.61% | +9.29% | +315.76% | +347.80% | 11.47B | ||
| +4.45% | +3.13% | -52.71% | -62.20% | 9.98B | ||
| +2.01% | +4.30% | +25.86% | +84.71% | 9.92B | ||
| Average | +0.51% | +0.94% | +51.18% | +39.36% | 26.71B | |
| Weighted average by Cap. | +0.05% | +0.05% | +41.84% | +23.50% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 9.64B 9.13B 8.46B 7.57B 13.64B 817B 15.09B 105B 38.92B 336B 36.23B 35.42B 1,446B | 9.52B 9.01B 8.35B 7.47B 13.46B 807B 14.9B 104B 38.43B 331B 35.77B 34.98B 1,428B |
| Net income | 1.79B 1.7B 1.57B 1.41B 2.53B 152B 2.8B 19.55B 7.23B 62.33B 6.73B 6.58B 269B | 2.13B 2.02B 1.87B 1.67B 3.01B 181B 3.34B 23.27B 8.6B 74.17B 8.01B 7.83B 320B |
| Net Debt | 3.54B 3.35B 3.1B 2.78B 5B 300B 5.54B 38.61B 14.28B 123B 13.29B 12.99B 530B | 491M 465M 431M 386M 695M 41.62B 769M 5.36B 1.98B 17.1B 1.85B 1.81B 73.68B |
More financial data
* Estimated data
Employees
7,570
Sector
Pharmaceuticals
Calendar
29/01/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/12/24 | 157.78 $ | -0.93% | 947,660 |
| 05/12/24 | 159.26 $ | -1.03% | 1,037,392 |
| 04/12/24 | 160.92 $ | +0.04% | 1,157,437 |
| 03/12/24 | 160.85 $ | -2.06% | 1,210,835 |
| 02/12/24 | 164.23 $ | +2.24% | 1,663,850 |
Delayed Quote Nasdaq, December 06, 2024 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
157.78USD
Average target price
253.83USD
Spread / Average Target
+60.88%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition